Sofinnova Investments, Inc.

Q3 2018 13F Holdings Report, Stock Holdings

Signature - Title
Nathalie Auber - Attorney-in-Fact
Location
Menlo Park, CA
Holdings as of
30 Sep 2018
Value $
$1,114,095,000
Num holdings
59
Filing time
14 Nov 2018, 17:40:26 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included ASND, Nucana Biomed, OBSVF, AMRN, and NTRA.
Previous filing
Q2 2018 - 14 Aug 2018
Next filing
Q4 2018 - 22 Feb 2019
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2018 Q3 compared to 2018 Q2 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Nathalie Auber Attorney-in-Fact Menlo Park, California 14 Nov 2018

Sofinnova Ventures, Inc. is filing this Form 13F on behalf of itself and the general partner entities of the investment funds for which it serves as the investment adviser, Sofinnova Management VII, L.L.C., Sofinnova Management VIII, L.L.C., Sofinnova Management IX, L.L.C., and Sofinnova BioEquities GP LLC.

Other Included Managers (2):

Num Name Location File Number
1 Crestline Management, LP Fort Worth, TX 028-14917
2 Blackstone Alternative Asset Management L.P. New York, NY